121 related articles for article (PubMed ID: 31818713)
1. Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma.
Huang HJ; Yang LY; Tung HJ; Ku FC; Wu RC; Tang YH; Chang WY; Jung SM; Wang CC; Lin CT; Liu FY; Lin G; Chen MY; Chou HH; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2020 Apr; 119(4):793-804. PubMed ID: 31818713
[TBL] [Abstract][Full Text] [Related]
2. Treatment failure in endometrial carcinoma.
Huang HJ; Tang YH; Chou HH; Yang LY; Chao A; Huang YT; Lin G; Liu FY; Chang TC; Lai CH
Int J Gynecol Cancer; 2014 Jun; 24(5):885-93. PubMed ID: 24819657
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma.
Hogen L; Vicus D; Ferguson SE; Gien LT; Nofech-Mozes S; Lennox GK; Bernardini MQ
Int J Gynecol Cancer; 2019 Sep; 29(7):1164-1169. PubMed ID: 31273067
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
5. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
[TBL] [Abstract][Full Text] [Related]
6. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
Diaz ES; Walts AE; Karlan BY; Walsh CS
Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
[TBL] [Abstract][Full Text] [Related]
9. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma.
Yoshida K; Yoshikawa N; Shirakawa A; Niimi K; Suzuki S; Kajiyama H; Kikkawa F
J Gynecol Oncol; 2019 Nov; 30(6):e85. PubMed ID: 31576683
[TBL] [Abstract][Full Text] [Related]
11. Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Gadducci A; Notarnicola M; Menichetti A; Lanfredini N; Fanucchi A; Cosio S
Eur J Gynaecol Oncol; 2016; 37(2):182-8. PubMed ID: 27172742
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer.
Lee M; Kim SW; Lee SH; Paek J; Yim GW; Kim GE; Kim S; Kim JH; Kim YT; Nam EJ
Int J Gynecol Cancer; 2011 Aug; 21(6):1032-9. PubMed ID: 21738040
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
14. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
[TBL] [Abstract][Full Text] [Related]
15. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma.
Kajiyama H; Shibata K; Mizuno M; Yamamoto E; Fujiwara S; Umezu T; Suzuki S; Nakanishi T; Nagasaka T; Kikkawa F
Int J Gynecol Cancer; 2012 Jun; 22(5):801-6. PubMed ID: 22617480
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
17. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
18. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
19. Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.
Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Sorio R; Rabaiotti E; Scambia G; Cormio G; Scarampi L; Greggi S; Savarese A; Marinaccio M; Scollo P; Pignata S
Int J Gynecol Cancer; 2011 Aug; 21(6):1063-70. PubMed ID: 21633300
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
